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Novelty Statement (100 words) - Currently 155 words
What is already known?
o Both DAFNE (Dose Adjustment For Normal Eating) DAFNE education and 
continuous subcutaneous insulin infusionCSII lower the levels of  HbA1c 
HbA1c in people with tType 1 diabetes. The size and duration of effect areis 
not well documented.
What this study has found?
o HbA1cHbA1c decreases with either intervention and the effect lasts at least 5 
years. Those with a high HbA1c HbA1c to start with have a very large decrease 
inof HbA1cHbA1c.  following intervention. CSIIContinuous subcutaneous 
insulin infusion is effective in lowering HbA1c HbA1c whether or not people 
havewith or without previous DAFNE Dose Adjustment For Normal Eating 
educationDAFNE already completed a DAFNE course.
What are the clinical implications of the study?
o DAFNEose Adjustment For Normal Eating educationAFNE and 
CSIIcontinuous subcutaneous insulin infusion  are both good options for 
people with a high HbA1cHbA1c. DAFNE Dose Adjustment For Normal 
Eating educationDAFNE should not be a prerequisite before CSIIcontinuous 
subcutaneous insulin infusion. should be considered in those with or without 
previous DAFNE training.
Abstract
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Abstract
Aim Background and aims:
The REPOSE study described the relative effectiveness of insulin pumps compared to multiple daily injections over two years. OurThois 
observational study investigated the effect of DAFNEDose Adjustment For Normal Eating educationDAFNE and CSIIcontinuous 
subcutaneous insulin infusion  in clinical practice.
Methods Methods:
Within NHS Lothian, CSIIcontinuous subcutaneous insulin infusion  started in 2004 and DAFNE Dose Adjustment For Normal Eating 
education began DAFNE in 2006.  there are 4,617 people with Type 1 diabetes over 18 years. CSII started in 2004 and DAFNE in 2006. We 
extracted anonymizsed data from the national database that includedfor all those aged >over 18 years with tType 1 diabetes  recorded as 
having a Dose Adjustment For Normal Eating DAFNE course or CSIIcontinuous subcutaneous insulin infusion start date (n = 4,617). 
Results Results: 
In total, 956 persons receivedhad DAFNEDose Adjustment For Normal Eating educationDAFNE, and 505 had received an insulin pump, of 
which 208 of whom had DAFNE Dose Adjustment For Normal Eating educationDAFNE followed by insulin pump. Mean (SD) HbA1c HbA1c 
before DAFNE Dose Adjustment For Normal Eating DAFNE education was 68 (15) mmol/mol (8.4% [(1.4%])) and 66 (13) mmol/mol (8.2% 
[(1.2%])) before CSIIcontinuous subcutaneous insulin infusion. In the year following DAFNE Dose Adjustment For Normal Eating 
educationDAFNE, the mean fall in within- person HbA1c HbA1c was 3.8 mmol/mol (95% CI 4.0  to 3.4;: (0.3% [(0.4% to 0.3%)]). Those with 
the poorest control (HbA1c HbA1c ≥ 85 mmol/mol: [(9.9%])) experienced the largest decline (15.7 mmol/mol: [1.4%]). Those in the lowest 
HbA1c HbA1c band at initiation (< 53 mmol/mmol: [7.0%])) experienced a rise.
In the year following CSIIcontinuous subcutaneous insulin infusion initiation there was a mean fall in within- person HbA1c HbA1c of 6.6 
mmol/mol ([6.8 to, 6.4;] (0.6% [0.6% to, 0.6%]).  In those with the poorest control (HbA1c HbA1c ≥ 85 mmol/mol: [(9.9%])), the mean fall in 
HbA1c HbA1c was 22.2 mmol/mol ([23 to, 21;] (2.0% [2.1% to, 1.9%]). CCSIIontinuous subcutaneous insulin infusion  effectiveness was not 
different with or without DAFNE Dose Adjustment For Normal Eating educationDAFNE. The effects of both interventions were sustained 
over 5five years.
Conclusions Conclusions:
Both DAFNE Dose Adjustment For Normal Eating educationDAFNE and insulin pump therapy had the greatest effect on HbA1c HbA1c in those 
with higher baseline values. There was little difference to attained HbA1c HbA1c when Dose Adjustment For Normal Eating educationDAFNE 
was introduced before insulin pump therapy. 
<Typesetter: Format the reference citations throughout the text in the DME journal style, thanks.>
Commented [DH3]:  Author query: Note that the Aim of 
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<H1>Introduction
The challenges of managing tType 1 diabetes are well known. People with this condition require insulin for survival and there is a need to 
achieve glycaemic control that reduces the risk of long-term microvascular and macrovascular complications [1,2] (1) (2). Many people 
with diabetes in the UK, and indeed throughout the world-wide, have higher levels of HbA1c HbA1cs than is recommended [3,4] (3) (4). The 
use of structured education packages [5] (5)  and technologies such as continuous subcutaneous insulin infusion (CSII) provide 
opportunities to improve their self-management of diabetes and outcomes. The recent Relative Effectiveness of Pumps Over Structured 
Education (REPOSE) study described the relative effectiveness of CSII compared withto MDI, both with structured education in a 2-two 
year cluster randomizsed trial [6] (6).
Currently within NHS Lothian there are 4,617 people with tType 1 diabetes aged >over the age of 18 years. A CSII service was started in 
NHS Lothian in 2004, and the DAFNE (DAFNE (Dose Adjustment For Normal Eating)  (DAFNE) education programme was introduced in 
2006. We wished aimed to examine the longer-term effects of the DAFNE course and CSII therapy on HbA1c HbA1c in our local population.
<H1>Methods
Core data relating to the diabetes care of over > 99% of people with diabetes in the Lothian region areis held on the national diabetes 
database, SCI Diabetes. After obtaining Caldicott Guardian permission wWe extracted anonymizsed data from this databasesystem that 
includedfor  all those individuals recorded as having a start date for a DAFNE course (n = 956) and those all in receipt of an insulin pump (n 
= 505), either with (n = 208) or without prior DAFNE (n = 297). From the electronic health records, w We extracted from the electronic 
health record all the available HbA1cHbA1c data covering time periods both retrospective and prospective to the intervention for these 
individuals. For each 12- month period before and after the intervention, the median value of multiple measures in that 12- months period 
was used for eachthat individual was used. 
Initial tabulations were made showing the average within- person difference in HbA1c HbA1c across time both retrospective and 
prospective to the intervention date. Both median and interquartile ranges (IQR) and means and 95% confidence intervals (95% CI) of the 
within- person difference for each 12- month block before and after the interventions were summarizsed across all persons. Tabulations 
and figures were also generated showing these data by strata of age, initial HbA1cHbA1c level, sex and diabetes duration categories. In 
these tabulations, those who had DAFNE then pump had their HbA1c HbA1c data used for evaluating DAFNE right- censored upon the date 
of pump receipt. For those receiving an insulin pump, analyses were further stratified by those with and without prior DAFNE. 
We chose to describe the response in five5 different initial HbA1c HbA1c groups.  Initially wWe were going to describe the HbA1c HbA1c 
change based on the HbA1c HbA1c groups described as reported in the previous international comparison [3]published previously (3), but 
then we added two further extremes of HbA1c HbA1c control tohe give a more detailed analysis of response foron our population.
To confirm whether any apparently significant changes in HbA1c upHbA1c on receipt of the intervention (i.e. those with a confidence 
intervalsCI for the change not overlapping zero) were statistically significant, we fitted an additive mixed regression model with a random 
effect for the individual and a first order auto regressive correlation structure to account for temporal dependencies in these data within 
individuals. Time was scaled relative to the intervention. All models included age at diagnosis of diabetes, current age group, sex and, 
initial HbA1c HbA1c band. Significant periods of change were identified as previously described [7] (7). All analyses used the R statistical 
package. 
<H2>Ethical approval
This was an audit/observational study. We obtained Caldicott Guardian permission to review the anonymized data and did not require 
Ethics committee approval.
<H1>Results
In total, 956 persons had ever had received DAFNE, 505 had ever received an insulin pump, of whomich 208 had DAFNE followed by pump. 
As summarizsed in Table 1, the median time period of observation in the diabetes registry prior to DAFNE was 10–-11 years, was 4 years 
post- DAFNE and post- pump, and was slightly longer at 6 years for those receiving DAFNE and then going on to a receive a pump. The 
median number of HbA1c HbA1c values per 12- month period was 1.5 measures per person across this time period. 
<INSERT TABLE 1> 
<H2>DAFNE
Figure 1aa shows the median and IQR of the within- person difference in HbA1c HbA1c across time compared withto the values in the 12 
months prior to the DAFNE initiation date. The mean (95% CI) change across time and the median (IQR) are summarizsed for all persons 
combined and by sex gender in Table 2. The data are shown in detail by other strata of interest in supplementary Tables S1 and S5.
For DAFNE, it can be seen that the HbA1c HbA1c in the 12 months preceding DAFNE initiation was not significantlymuch  different to the 
values at the time of initiation of DAFNE.  Earlier values were slightly higher than at initiation. Then, in the year following DAFNE, the mean 
fall in within- person HbA1c HbA1c was 3.8 mmol/mol (95% CI 4.0 to 3.4;: (0.3% [(0.4% to 0.3%])) compared to with the HbA1c HbA1c in the 
Commented [DH4]:  Author query: Please check that the 
hierarchy of the headings throughout the paper is 
satisfactory. 
Commented [DH5]:  Author query: "MDI" is not one of 
the journal's approved abbreviations therefore please 
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year prior to DAFNE.  Overall, this fall decrease was broadly sustained over time. The decreasefall with DAFNE was slightly greater in 
women than men (Table 2). There were clear differences in the magnitude of the HbA1c HbA1c change with DAFNE, depending on the 
HbA1c HbA1c level uponin the at  initiation of DAFNE (Fig.ure 2aa, Supplementary Table S1); those with the poorest control (HbA1c HbA1c ≥ 
85 mmol/mol [(9.9%])) experienced the largest decline, with a mean within- person change in HbA1c HbA1c of 15.7 mmol/mol (1.4%), and 
indeed those in the lowest HbA1c HbA1c band at initiation (< 53 mmol/mmol [(7.0%])) experienced an increase rise. Difference in change in 
HbA1c HbA1c with DAFNE did not show a large variation by either age band or and duration (Supplementary Tables S1 and S6), other than 
in  that those aged > 65 years and in those with duration < 10 years duration, who experienced had  slightly less change. 
<INSERT FIGURE 1>
<INSERT FIGURE 2> 
<INSERT TABLE 2> 
<H2>CSII
Figure 1 shows the median and IQR of the within- person difference in HbA1c HbA1c across time compared withto the values in the 12 
months prior to the CSII initiation date, separated by whether there was (Fig.ure 1bb) or was no’t (Fig.ure 1cc) prior DAFNE. The mean 
(95% CI) change across time and the median (IQR) are summarizsed for all CSII recipients, combined and by sex gender in Table 2. The data 
are shown in detail by other strata of interest in supplementary Table S2. Data for CSII recipients, separated into those with and without 
prior DAFNE, are summarizsed in Supplementary Tables S3 and S7. 
For CSII, it can be seen that the HbA1c HbA1c in the 12 months preceding CSII initiation was not significantlymuch different to the values at 
the time of initiation of CSII.  Earlier values were slightly higher than at initiation. Then, in the year following CSII initiation, there was a 
large mean fall decrease in within- person HbA1c HbA1c of  6.6 mmol/mol ([6.8 to, 6.4)] (0.6%).  This decreasefall was sustained over time. 
The mean fall in HbA1c HbA1c with CSII in the year following initiation was 5.2 mmol/mol ([5.5 to, 4.9)] (0.5%) in men and 7.4 mmol/mol 
([7.7 to, 7.2)] (0.7%) in women ( Table 2). CSII was effective regardless of whether there was or was not prior DAFNE (Fig.ure 1b,c b&c, 
Supplementary Table S3). There were clear differences in the magnitude and direction of HbA1c HbA1c change with CSII depending on the 
HbA1c HbA1c level at initiation, as shown in Fig.ure 2bb and Supplementary Table S2. In those with the poorest control (HbA1c HbA1c ≥ 85 
mmol/mol [(9.9%])), the mean fall in HbA1c HbA1c in the year following receipt of CSII receipt was 22.2 mmol/mol ([23 to,  21.4)] (2.0% 
[2.1% to 1.9%]), whereas in those with HbA1c HbA1c at initiation < 53 mmol/mol (7.0%) at initiation, values remainedstayed about the 
same. Difference in change in HbA1c HbA1c with CSII did not show a large variation by age band and wereseemed slightly less in those 
receiving CSII within 5five years of onset of diabetes. 
Adjusted for multiple comparisons within individuals, the changes in HbA1c HbA1c with both DAFNE and CSII in the 4four years following 
receipt of these interventions were highly significant (all at pP < 0.0001). The regression model showed that the fall in HbA1c HbA1c 
remained significant when  adjusted for other variables. Although in those CSII recipients without prior DAFNE the change in HbA1c HbA1c 
with CSII was very slightly greater than in those with prior DAFNE (Fig. 1b,cb&c), this was not a significant difference in effect when 
adjusted for other covariates. 
<H1>Discussion
These observational data have shown that, overall, the provision of a DAFNE course or CSII, (with associated education) decreases 
HbA1cHbA1c. The effect is due mainly to a decrease in those with higher HbA1c HbA1c values before either intervention. In those with an 
HbA1c HbA1c in a more acceptable range, these interventions have little effect upon overall HbA1c, HbA1c and in some individuals with low 
values of HbA1c HbA1c at initiation there is a slight rise in HbA1c HbA1c with DAFNE. This is not surprising, as the purpose of the 
interventions in those with tight glycaemic control is to decrease hypoglycaemia and improve quality of life, as demonstrated by the Irish 
DAFNE Study Group [8] (8), rather than to change overall HbA1cHbA1c. Further work research will explore the impact on these clinical 
events when data accrue. 
We have also demonstrated that the effect of CSII or DAFNE is maintained for at least 5five years after the intervention. We have 
demonstrated that, within the service provided byin NHS Lothian, introducing CSII without a prior DAFNE course is at least as effective as 
with a prior DAFNE course. Thus, our data suggest that in those warranting CSII, this should not be delayed if DAFNE is not available. 
 It is interesting to note that HbA1c HbA1c changed in the few months before initiating stituting DAFNE and before CSII therapy in those 
who had not previously received DAFNE training. This is likely to reflect the preparation process for starting DAFNE and CSII in Lothian. The 
CSII preparation involves a detailed review and education about carbohydrate counting and dose adjustment.
Our results are similar towith those of the original DAFNE publication [5], which  (5) as they noted a mean HbA1c HbA1c decrease of 5 
mmol/mol (0.5%) when compared aftert  1 year. In our analysis, the decrease following DAFNE was 3 mmol/mol (0.3%) in the first year 
after DAFNE, and this was maintained for 5five years. There are a number of possible explanations for any small minor difference 
recorded. Many of our population had already been exposed to some carbohydrate CHO counting training, and the mean HbA1c HbA1c at 
the time of intervention was 68 mmol/mol (8.4%), significantly lower than the 79 mmol/mol (9.4%) in the original DAFNE study. In a 1one -
year follow- up of 639 people who completed DAFNE training, HbA1c HbA1c decreased from 69 to 66 mmol/mol (8.5% to 8.2%) [9] (9). We 
have found a similar, prolonged decrease inof HbA1c, HbA1c but have also havdemonstratede shown the a different response from those 
Commented [DH7]:  Author query: Check the expansion 
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who start with a higher or lower HbA1cHbA1c. Our longer follow- up demonstrating an ongoing effect on a large cohort of people who have 
completed DAFNE is also important and adds to a previous smaller report relating to 141 people followed up for 44 months (10).
Our results also contrast with and add to the information from the recent REPOSE study [6] (6). In their cluster randomizsed controlled 
trial,  they reported a decreases inof HbA1c HbA1c at 2two years of 4.5 mmol/mol (0.4%) following DAFNE and of 9.3 mmol/mol (0.8%) 
following CSII were reported. We have been able to analyse our results for 4four years before and 5five years following the intervention, 
demonstrating a sustained effect that appears to bethat seems a little smaller than that noted in the REPOSE trial. Again, this is partly 
explained by our lower HbA1c HbA1c value at the time of the intervention (75 to 78 mmol/mol [(9.0% to 9.3%]) in REPOSE, 68 to 70 
mmol/mol [(8.4% to 8.6%]) in our study).   Our population was also different to the REPOSE study population,  as the policy in NHS Lothian 
is to give CSII to those who fulfil the National Institute for Health and Care Excellence criteria for CSII, whereas thoese individuals were 
excluded from the REPOSE study.
In addition, we have shown that adding CSII to those who have not taken part in a DAFNE course is at least as effective in lowering 
HbA1cHbA1c  as initiation in those who have received DAFNE. It is important to note, however, that knowledge and application of 
carbohydrate counting is assessed and addressed for each individual as part of the CSII referral and initiation process within NHS Lothian, 
and that people would not be considered for a pump without the appropriate skills.  We have, however, also demonstrated that adding 
CSII to those who have already received DAFNE provides further added benefit in lowering HbA1cHbA1c. 
A strength of this analysis is the use of routine clinical data, collected as part of clinical care, for the whole population in our area over a 
10ten-year period. Our study population is sufficiently large to enable a detailed analysis and we do not believe there has been any 
selection bias as those studied were identified on our comprehensive, population- wide database. Previous studies have involved far fewer 
individuals. We have also provided information on a group of individuals selected as wanting these interventions, a better reflection of the 
effects in real clinical practice.
During the time period of this analysis there has been a change of overall glycaemic control in the whole population with tType 1 diabetes 
in Lothian. Our regression analysis has, however, enabled us to ensure that the changes in HbA1c HbA1c within initiation of DAFNE and CSII 
were not attributable to any ongoing background downward trend in HbA1cHbA1c. Indeed, apart from the period immediately preceding 
and  immediately afterpost the intervention, the HbA1c HbA1c control was has been stable both in the before and after the interventions 
in this group.
A limitation of our study is that we have only investigated the effect of our interventions upon HbA1cHbA1c. We have not measured quality 
of life indicators, and do not believe that our information relating to hypoglycaemia is sufficiently accurate to be included in this analysis. It 
One must therefore be recogniszed that we are therefore failing to report on two very important aspects of diabetes care.
Despite these limitations, we can conclude that both interventions are effective in lowering HbA1cHbA1c. The effects are greater in those 
with a higher HbA1cHbA1c, and in our experience it is not necessary to have receivedhad a DAFNE course before introducing CSII. These 
data provide further information to influence guidelines and health policy.
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Table 1: Characteristics of each group
Ever DAFNE Ever CSII DAFNE then CSII
N (%) 956 (76.3) 505 (40.3) 208 (16.6) 
WomenFemale, N n (%) 523 (54.7) 307 (60.8) 121 (58.2) 
Age of Oonset, median (IQR) 20.1 (11.9, 30.8) 14.8 (9.0, 24.9) 16.4 (10.2, 26.9) 
Diabetes dDuration at pPump iInitiation, median (IQR) 19.8 (11.3, 28.3) 21.1 (12.5, 27.3) 
Diabetes dDuration at DAFNE iInitiation, median (IQR) 15.9 (7.4, 24.9) 18.3 (9.7, 25.0) 
Initial HbA1cHbA1c  (mmol/mol), median (IQR) 68 (60, 78) 66 (60, 75) 68 (60, 77) 
Initial HbA1cHbA1c (%), median (IQR) 8.4 (7.6, 9.3) 8.2 (7.6, 9.0) 8.3 (7.6, 9.2) 
Initial HbA1cHbA1c bBand 1, nN (%) 103 (11.4) 23 (11.1) 23 (11.1) 
Initial HbA1cHbA1c bBand 2, nN (%) 95 (10.6) 20 (9.6) 20 (9.6) 
Initial HbA1cHbA1c bBand 3, nN (%) 413 (45.9) 128 (61.5) 128 (61.5) 
Initial HbA1cHbA1c bBand 4, nN (%) 160 (17.8) 23 (11.1) 23 (11.1) 
Initial HbA1cHbA1c bBand 5, nN (%) 129 (14.3) 14 (6.7) 14 (6.7) 
Pump Ssttart yYear, (minimum, maximum) 2004, 2017 2009, 2017 
DAFNE Sstart yYear, (minimum, maximum) 2002, 2018 2006, 2016 
Time before CSII, median (IQR) 11.5 (15.1, 7.1) 10.6 (14.1, 7.3) 
Time before DAFNE, median (IQR) 10.5 (15.1, 5.6) 10.6 (14.1, 7.3) 
Time after CSII, median (IQR) 4.3 (2.9, 6.3) 4.3 (2.2, 5.1)
Time after DAFNE, median (IQR) 4.4 (2, 7) 6.2 (4.4, 8.1)
CSII, continuous subcutaneous insulin infusion; DAFNE, Dose Adjustment For Normal Eating  
Band 1 < 53 mmol/mol (< 7.0%);: bBand 2: 53 to 57 mmol/mol (7.0% to 7.4%);: bBand 3: 58 to 74 mmol/mol (7.5% to 8.9%);
 bBand 4: 75 to 84 mmol/mol (9.0% to 9.9%);: bBand 5 > 85 mmol/mol (> 10%)
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Table 2 Difference in HbA1C (mmol/mol) with respect to intervention initiation date. (rResults in % units are sshown in Supplementary Table S4)
Difference with respect to DAFNE initiation date overall
Years since DAFNE -4 -3 -2 -1 0 1 2 3 4 
n
median ([IQR)]*
mean (95% CI)**
2,058 
 0.4 [0.1, 0.7] 
 -0.5 (-6.0 to, 6.0) 
2,225 
 1.5 [1.2, 1.7] 
 0.0 (-4.5 to, 6.0) 
2,775 
 1.1 [0.9, 1.2] 
 0.0 (-2.0 to, 3.0) 
4,004 
 -0.2 [-0.3, -0.1] 
 0.0 (-1.0 to, 1.0) 
3,163 
 -3.8 [-4.0, -3.6] 
 -3.0 (-8.5 to, 2.0) 
2,340 
 -3.7 [-4.0, -3.4] 
 -2.5 (-10.5 to, 3.5) 
1,754 
 -3.2 [-3.5, -2.8] 
 -2.5 (-10.0 to, 5.0) 
1,502 
 -3.6 [-4.0, -3.2] 
 -3.0 (-12.0 to ,5.0) 
1,233 
 -4.6 [-5.1, -4.2] 
 -3.0 (-13.5 to ,5.0) 
Difference with respect to DAFNE initiation date by sex
Female Women 
1,149 
 0.4 [-0.1, 0.8] 
 -0.5 (-7.0 to, 6.5) 
1,251 
 1.4 [1.1, 1.8] 
 0.5 (-5.0 to, 6.0) 
1,541 
 1.0 [0.8, 1.3] 
 0.0 (-2.0 to, 2.5) 
2,222 
 -0.2 [-0.3, -0.1] 
 0.0 (-1.0 to, 0.5) 
1,792 
 -4.4 [-4.7, -4.1] 
 -3.5 (-9.0 to, 1.6) 
1,358 
 -5.2 [-5.6, -4.8] 
 -3.5 (-12.0 to ,3.0) 
1,026 
 -4.0 [-4.5, -3.5] 
 -3.5 (-10.5 to, 4.0) 
882 
 -3.7 [-4.3, -3.2] 
 -3.0 (-13.0 to, 5.0) 
745 
 -4.5 [-5.1, -3.9] 
 -3.0 (-14.0 to, 5.0) 
Menale 
909 
 0.4 [0.0, 0.8] 
 -0.5 (-5.0 to ,5.0) 
974 
 1.5 [1.2, 1.9] 
 0.0 (-4.0 to, 6.0) 
1,234 
 1.1 [0.9, 1.3] 
 0.0 (-1.5 to ,3.0) 
1,782 
 -0.2 [-0.3, -0.1] 
 0.0 (-1.5 to, 1.0) 
1,371 
 -3.1 [-3.4, -2.8] 
 -3.0 (-7.5 to, 3.0) 
982 
 -1.7 [-2.1, -1.3] 
 -1.0 (-6.5 to, 5.0) 
728 
 -2.0 [-2.5, -1.5] 
 -1.5 (-9.2 to ,5.0) 
620 
 -3.4 [-4.0, -2.9] 
 -3.0 (-9.5 to, 4.5) 
488 
 -4.9 [-5.6, -4.2] 
 -2.5 (-13.0 to, 4.0) 
Difference with respect to CSII initiation date overall
Years since CII -4 -3 -2 -1 0 1 2 3 4 
n
median ([IQR)]*
mean (95% CI)**
1,102 
 0.7 [0.3, 1.1] 
 1.0 (-5.5 to, 6.3) 
1,534 
 1.5 [1.2, 1.8] 
 1.5 (-4.0 to, 6.0) 
1,843
 1.5 [1.4, 1.7] 
 0.2 (-1.3 to, 2.8) 
2,521 
 -0.4 [-0.4, -0.3] 
 0.0 (-1.8 to, 1.0) 
2,715 
 -6.6 [-6.8, -6.4] 
 -5.5 (-10.8 to ,-0.5) 
2,583 
 -7.3 [-7.5, -7.1] 
 -6.7 (-12.0 to ,-1.0) 
2,116 
 -5.8 [-6.1, -5.6] 
 -5.1 (-12.0 to, 0.3) 
1,699 
 -7.2 [-7.5, -6.9] 
 -5.5 (-14.3 to, 0.5) 
1,278 
 -6.1 [-6.4, -5.8] 
 -5.3 (-12.2 to, 0.3) 
Difference with respect to CSII initiation date by sex
Female Women
695 
 -0.1 [-0.6, 0.4] 
 1.0 (-7.0 to, 6.0) 
1,012 
 1.4 [1.0, 1.8] 
 2.0 (-4.0 to, 5.5) 
1,142 
 1.3 [1.2, 1.5] 
 0.1 (-1.5 to, 2.8) 
1,474 
 -0.3 [-0.4, -0.2] 
 0.0 (-1.7 to, 1.4) 
1,709 
 -7.4 [-7.7, -7.2] 
 -6.5 (-11.5 to, -1.5) 
1,659 
 -8.0 [-8.3, -7.7] 
 -7.0 (-13.2 to, -1.7) 
1,379 
 -6.3 [-6.6, -6.0] 
 -5.0 (-13.0 to, 0.3) 
1,128 
 -8.1 [-8.5, -7.7] 
 -5.7 (-16.0 to, 0.5) 
881 
 -6.8 [-7.3, -6.4] 
 -6.0 (-13.5 to, -0.2) 
Menale 
407 
 2.1 [1.6, 2.6] 
 1.0 (-3.5 to, 7.0) 
522 
 1.8 [1.4, 2.2] 
 1.0 (-4.0 to, 6.5) 
701 
 1.8 [1.6, 2.1] 
 0.8 (-1.0 to, 3.0) 
1,047 
 -0.4 [-0.5, -0.3] 
 -0.5 (-2.0 to, 0.5) 
1,006 
 -5.2 [-5.5, -4.9] 
 -4.0 (-10.0 to, 1.4) 
924 
 -6.1 [-6.4, -5.8] 
 -5.0 (-11.0 to, -0.5) 
737 
 -5.0 [-5.4, -4.7] 
 -5.2 (-9.7 to, 0.0) 
571 
 -5.5 [-5.9, -5.1] 
 -5.0 (-11.2 to, 0.0) 
397 
 -4.5 [-4.9, -4.1] 
 -4.0 (-8.5 to, 0.3) 
CSII, continuous subcutaneous insulin infusion; DAFNE, Dose Adjustment For Normal Eating  
HbA1c HbA1c values in International Federation of Clinical ChemistryIFCC mmol/mol units
* IQR,  = interquartile range in square brackets 
** 95% CI, = 95% confidence interval in round brackets 
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FIGUREigure 1 Median dDifference in HbA1c HbA1c over time compared withto  HbA1c HbA1c at dDate of iIntervention Commented [DH10]:  Author query: For Figure 1, add 
details of parts (A), (B) and (C) to the Figure 1 legend. 
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FIGUREigure 2 Median dDifference in HbA1c HbA1c over time compared withto HbA1c HbA1c at dDate of iIntervention by HbA1c HbA1c 
band at date of intervention
<H1>Supporting Information
Additional supporting information may be found online in the Supporting Information section at the 
end of the article.
Table S1 Difference in HbA1C over time with respect to DAFNE initiation date.
Table S2 Difference in HbA1C across time with respect to CSII initiation date by strata.
Table S3 Difference in HbA1C across time with respect to CSII initiation date stratified by DAFNE.
Table S4 Difference in HbA1C with respect to intervention initiation date (HbA1C in percentage units).
Table S5 Difference in HbA1C over time with respect to DAFNE initiation date (HbA1C percentage units). 
Table S6 Difference in HbA1C across time with respect to CSII initiation date by strata (HbA1C in percentage units).
Table S7 Difference in HbA1C across time with respect to CSII initiation date stratified by DAFNE (HbA1C in percentage units).
<TYPESETTER: Ensure that the Supporting Information, which follows on from here, is not published with the main text.>
Commented [DH11]:  Author query: For Figure 2, add 
details of parts (A) and (B) to the Figure 2 legend. 
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Supplementary Table 1 Difference in HbA1C over time with respect to DAFNE initiation date
All DAFNE recipients
Years since DAFNE -4 -3 -2 -1 0 1 2 3 4 
n
median[IQR]*
mean(95%CI)**
2,058 
 0.4 [0.1, 0.7] 
 -0.5 (-6.0,6.0) 
2,225 
 1.5 [1.2, 1.7] 
 0.0 (-4.5,6.0) 
2,775 
 1.1 [0.9, 1.2] 
 0.0 (-2.0,3.0) 
4,004 
 -0.2 [-0.3, -0.1] 
 0.0 (-1.0,1.0) 
3,163 
 -3.8 [-4.0, -3.6] 
 -3.0 (-8.5,2.0) 
2,340 
 -3.7 [-4.0, -3.4] 
 -2.5 (-10.5,3.5) 
1,754 
 -3.2 [-3.5, -2.8] 
 -2.5 (-10.0,5.0) 
1,502 
 -3.6 [-4.0, -3.2] 
 -3.0 (-12.0,5.0) 
1,233 
 -4.6 [-5.1, -4.2] 
 -3.0 (-13.5,5.0) 
All DAFNE recipients stratified by HbA1C
HbA1c -4 -3 -2 -1 0 1 2 3 4 
(-Inf,53] 
154 
 7.6 [6.5, 8.7] 
 5.5 (-0.5,11.5) 
211 
 6.3 [5.4, 7.2] 
 4.0 (-0.5,7.5) 
337 
 3.3 [2.6, 3.9] 
 0.0 (-1.5,3.0) 
479 
 0.5 [0.4, 0.7] 
 0.0 (-1.0,0.5) 
334 
 3.4 [3.1, 3.7] 
 3.0 (0.0,6.0) 
236 
 4.2 [3.5, 4.8] 
 2.5 (-1.5,8.0) 
158 
 8.8 [7.8, 9.8] 
 6.0 (1.0,21.5) 
122 
 9.4 [8.5, 10.3] 
 9.5 (2.4,16.0) 
88 
 10.4 [9.4, 11.5] 
 13.0 (4.0,16.0) 
(53,58] 
220 
 4.9 [4.1, 5.7] 
 1.8 (-2.0,6.6) 
255 
 4.9 [4.1, 5.6] 
 2.0 (-1.5,7.8) 
285 
 1.8 [1.5, 2.2] 
 0.5 (-1.0,4.0) 
479 
 0.0 [-0.2, 0.2] 
 0.0 (-1.0,0.0) 
311 
 1.2 [0.8, 1.6] 
 1.0 (-4.0,5.0) 
268 
 3.8 [3.3, 4.3] 
 2.0 (-1.0,5.9) 
188 
 2.5 [1.9, 3.2] 
 0.5 (-3.0,5.5) 
159 
 1.7 [1.1, 2.3] 
 2.0 (-4.0,5.0) 
116 
 1.6 [0.9, 2.3] 
 2.0 (-3.0,5.5) 
(58,75] 
943 
 1.2 [0.8, 1.6] 
 0.0 (-5.0,5.0) 
1,048 
 1.9 [1.6, 2.3] 
 1.0 (-3.5,6.0) 
1,317 
 0.6 [0.4, 0.8] 
 0.0 (-1.5,2.5) 
1,863 
 -0.1 [-0.2, -0.1] 
 0.0 (-1.0,1.0) 
1,516 
 -2.2 [-2.5, -2.0] 
 -2.8 (-7.0,1.5) 
1,047 
 -1.5 [-1.8, -1.2] 
 -2.0 (-7.0,3.0) 
749 
 0.3 [-0.1, 0.8] 
 -1.5 (-6.0,6.0) 
623 
 -0.4 [-0.9, 0.1] 
 -1.0 (-6.0,5.5) 
544 
 -0.6 [-1.0, -0.1] 
 -1.5 (-7.0,4.5) 
(75,85] 
411 
 -0.2 [-0.8, 0.4] 
 -2.0 (-6.0,5.0) 
392 
 1.0 [0.4, 1.6] 
 -0.8 (-6.0,6.5) 
474 
 1.0 [0.7, 1.4] 
 0.0 (-2.0,2.0) 
731 
 -0.2 [-0.3, 0.0] 
 0.0 (-1.5,0.5) 
551 
 -5.7 [-6.2, -5.3] 
 -6.0 (-12.8,-1.5) 
454 
 -7.1 [-7.6, -6.5] 
 -8.5 (-14.5,0.0) 
348 
 -8.2 [-8.7, -7.6] 
 -9.0 (-18.0,-1.0) 
246 
 -5.9 [-6.6, -5.2] 
 -8.0 (-13.0,1.0) 
208 
 -6.0 [-6.7, -5.2] 
 -7.0 (-14.0,1.2) 
(85, Inf] 
330 
 -7.6 [-8.7, -6.5] 
 -7.5 (-17.0,3.8) 
319 
 -5.3 [-6.0, -4.6] 
 -4.0 (-10.5,1.0) 
362 
 0.0 [-0.5, 0.5] 
 0.0 (-4.5,3.5) 
452 
 -1.3 [-1.7, -0.8] 
 0.0 (-3.0,1.5) 
451 
 -15.7 [-16.6, -14.9] 
 -13.0 (-29.0,-6.2) 
335 
 -17.7 [-18.8, -16.6] 
 -17.0 (-31.0,-6.0) 
311 
 -15.6 [-16.7, -14.5] 
 -12.0 (-29.5,-2.2) 
352 
 -14.6 [-15.6, -13.7] 
 -15.0 (-26.0,-2.0) 
277 
 -19.0 [-20.1, -17.9] 
 -18.0 (-28.0,-6.0) 
All DAFNE recipients stratified by age
Age group -4 -3 -2 -1 0 1 2 3 4 
(13,19] 
372 
 -3.1 [-4.0, -2.2] 
 -3.8 (-11.0,6.0) 
278 
 1.3 [0.3, 2.3] 
 0.2 (-8.0,6.2) 
202 
 2.2 [1.0, 3.3] 
 0.0 (-3.0,3.0) 
151 
 1.5 [1.0, 2.0] 
 0.0 (-0.5,2.0) 
72 
 4.3 [3.1, 5.5] 
 4.0 (-3.8,11.9) 
9 
 9.2 [2.1, 16.3] 
 4.0 (-4.5,30.0) 
NA NA NA 
(19,25] 
244 
 4.7 [3.3, 6.1] 
 1.8 (-4.2,10.2) 
290 
 3.5 [2.6, 4.5] 
 3.5 (-6.0,9.0) 
421 
 2.0 [1.5, 2.4] 
 0.0 (-3.0,4.0) 
676 
 -0.5 [-0.8, -0.3] 
 0.0 (-2.0,0.0) 
460 
 -3.6 [-4.5, -2.8] 
 -2.5 (-8.0,7.0) 
321 
 -2.8 [-3.9, -1.7] 
 -1.0 (-9.5,9.0) 
221 
 -2.6 [-3.7, -1.4] 
 -2.0 (-10.0,6.5) 
184 
 -6.6 [-8.2, -4.9] 
 -3.0 (-25.0,6.0) 
112 
 -1.4 [-3.4, 0.7] 
 2.0 (-18.5,13.0) 
(25,45] 
839 
 0.5 [0.2, 0.9] 
 -0.5 (-6.0,5.0) 
918 
 1.1 [0.7, 1.5] 
 0.0 (-4.0,5.5) 
1,264 
 1.2 [1.0, 1.4] 
 0.0 (-1.5,2.5) 
1,848 
 -0.2 [-0.3, -0.1] 
 0.0 (-1.0,1.0) 
1,514 
 -4.5 [-4.7, -4.2] 
 -4.0 (-10.0,2.0) 
1,165 
 -4.6 [-5.0, -4.2] 
 -3.0 (-12.0,3.0) 
847 
 -4.8 [-5.3, -4.2] 
 -4.0 (-12.0,5.0) 
718 
 -4.7 [-5.2, -4.2] 
 -4.5 (-12.0,4.5) 
564 
 -7.8 [-8.5, -7.1] 
 -7.0 (-15.0,3.0) 
(45,65] 
556 
 0.2 [-0.4, 0.7] 
 -0.5 (-5.5,5.0) 
671 
 0.9 [0.6, 1.3] 
 0.0 (-4.0,5.0) 
789 
 0.1 [-0.1, 0.3] 
 0.0 (-2.0,3.0) 
1,146 
 -0.1 [-0.2, 0.0] 
 0.0 (-1.0,1.0) 
926 
 -3.9 [-4.2, -3.6] 
 -3.0 (-7.0,1.0) 
698 
 -2.8 [-3.1, -2.4] 
 -2.0 (-8.0,2.5) 
560 
 -1.4 [-1.9, -0.9] 
 -1.0 (-7.0,5.0) 
480 
 -0.9 [-1.4, -0.3] 
 -2.0 (-8.5,7.0) 
457 
 -1.3 [-1.8, -0.8] 
 -2.0 (-7.5,5.0) 
(65, Inf] 
47 
 5.2 [3.9, 6.5] 
 3.5 (1.0,6.0) 
68 
 3.7 [2.8, 4.6] 
 2.5 (-0.5,7.5) 
99 
 0.8 [0.5, 1.2] 
 0.5 (0.0,2.5) 
183 
 -0.7 [-0.9, -0.4] 
 0.0 (-2.0,0.0) 
191 
 -1.9 [-2.3, -1.5] 
 -2.0 (-5.5,1.0) 
147 
 -3.9 [-4.6, -3.2] 
 -3.0 (-6.5,1.0) 
126 
 -1.8 [-3.0, -0.6] 
 -1.0 (-5.6,2.0) 
120 
 -3.6 [-4.8, -2.4] 
 -1.5 (-8.0,5.0) 
100 
 -5.4 [-6.7, -4.1] 
 -2.2 (-12.0,3.2) 
All DAFNE recipients stratified by duration
Duration -4 -3 -2 -1 0 1 2 3 4 
(-Inf,5] 
468 
 0.5 [-0.5, 1.4] 
 -2.0 (-8.5,6.5) 
512 
 1.4 [0.6, 2.1] 
 -0.5 (-8.6,8.0) 
713 
 2.2 [1.7, 2.7] 
 0.0 (-2.0,3.0) 
927 
 -0.2 [-0.3, 0.0] 
 0.0 (-0.5,1.0) 
605 
 0.2 [-0.4, 0.8] 
 0.5 (-4.5,8.0) 
387 
 2.9 [2.0, 3.9] 
 3.5 (-2.2,13.0) 
204 
 3.6 [2.2, 4.9] 
 2.0 (-5.1,13.9) 
94 
 -0.2 [-2.3, 1.9] 
 1.0 (-7.4,12.0) 
10 
 -4.0 [-12.9, 4.9] 
 -20.0 (-20.0,27.0) 
(5,10] 389 408 501 665 463 359 278 269 249 
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 0.4 [-0.4, 1.3] 
 1.0 (-7.0,7.5) 
 2.4 [1.7, 3.0] 
 1.5 (-4.0,6.5) 
 1.1 [0.8, 1.4] 
 0.0 (-2.0,3.0) 
 -0.1 [-0.3, 0.1] 
 0.0 (-1.5,0.5) 
 -2.8 [-3.4, -2.3] 
 -2.5 (-7.0,2.0) 
 -3.0 [-3.7, -2.4] 
 -1.0 (-7.2,4.5) 
 -3.2 [-4.2, -2.1] 
 -2.0 (-11.5,7.9) 
 0.4 [-0.6, 1.4] 
 2.0 (-8.0,10.5) 
 -1.3 [-2.4, -0.3] 
 -1.0 (-9.0,6.5) 
(10,15] 
327 
 -1.0 [-1.7, -0.4] 
 -2.0 (-8.0,4.0) 
315 
 0.4 [-0.3, 1.1] 
 -1.0 (-5.5,5.5) 
339 
 0.4 [0.1, 0.8] 
 0.0 (-2.0,3.5) 
536 
 -0.7 [-1.0, -0.5] 
 0.0 (-1.5,1.0) 
439 
 -6.7 [-7.3, -6.1] 
 -5.0 (-11.5,1.0) 
338 
 -8.2 [-9.0, -7.4] 
 -6.0 (-17.8,2.4) 
254 
 -5.5 [-6.3, -4.7] 
 -3.5 (-11.0,0.5) 
286 
 -5.5 [-6.3, -4.7] 
 -4.5 (-13.0,2.5) 
204 
 -7.8 [-8.8, -6.9] 
 -9.5 (-15.0,2.0) 
(15,20] 
303 
 1.4 [0.8, 2.0] 
 0.0 (-4.0,5.0) 
332 
 3.0 [2.5, 3.5] 
 1.0 (-2.6,7.5) 
406 
 0.2 [-0.1, 0.5] 
 0.0 (-1.5,2.0) 
570 
 0.0 [-0.2, 0.2] 
 0.0 (-1.5,1.0) 
511 
 -5.8 [-6.3, -5.2] 
 -4.0 (-9.0,1.0) 
368 
 -6.4 [-7.2, -5.6] 
 -5.0 (-14.0,2.0) 
230 
 -8.3 [-9.3, -7.4] 
 -6.2 (-14.0,1.0) 
190 
 -10.0 [-11.0, -9.1] 
 -6.5 (-26.0,2.0) 
143 
 -6.6 [-8.0, -5.2] 
 -5.5 (-12.5,5.0) 
(20, Inf] 
571 
 0.5 [0.2, 0.9] 
 0.0 (-4.0,5.0) 
658 
 0.7 [0.5, 1.0] 
 0.0 (-3.0,4.4) 
816 
 0.7 [0.6, 0.9] 
 0.0 (-1.5,3.0) 
1,306 
 -0.1 [-0.2, 0.0] 
 0.0 (-1.0,0.5) 
1,145 
 -4.4 [-4.7, -4.1] 
 -4.0 (-9.5,0.5) 
888 
 -4.1 [-4.4, -3.7] 
 -3.5 (-10.0,1.0) 
788 
 -2.7 [-3.1, -2.3] 
 -2.5 (-9.0,4.0) 
663 
 -3.1 [-3.6, -2.6] 
 -3.0 (-11.0,5.0) 
627 
 -4.5 [-5.1, -3.9] 
 -2.5 (-13.2,4.0) 
HbA1c values in IFCC mmol/mol units
* IQR = interquartile range in square brackets 
** 95% CI = 95% confidence interval in round brackets 
Page 21 of 36 Diabetic Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
17
Supplementary Table 2 Difference in HbA1C across time with respect to CSII initiation date by strata
All CSII recipients
Years since CII -4 -3 -2 -1 0 1 2 3 4 
n
median[IQR]*
mean(95%CI)**
1,102 
 0.7 [0.3, 1.1] 
 1.0 (-5.5,6.3) 
1,534 
 1.5 [1.2, 1.8] 
 1.5 (-4.0,6.0) 
1,843 
 1.5 [1.4, 1.7] 
 0.2 (-1.3,2.8) 
2,521 
 -0.4 [-0.4, -0.3] 
 0.0 (-1.8,1.0) 
2,715 
 -6.6 [-6.8, -6.4] 
 -5.5 (-10.8,-0.5) 
2,583 
 -7.3 [-7.5, -7.1] 
 -6.7 (-12.0,-1.0) 
2,116 
 -5.8 [-6.1, -5.6] 
 -5.1 (-12.0,0.3) 
1,699 
 -7.2 [-7.5, -6.9] 
 -5.5 (-14.3,0.5) 
1,278 
 -6.1 [-6.4, -5.8] 
 -5.3 (-12.2,0.3) 
All CSII recipients stratified by HbA1c
HbA1c -48 to -36 -36 to -24 -24 to -12 -12 to 0 0 to 12 12 to 24 24 to 36 36 to 48 48 to 60
(-Inf,53] 
126 
 3.8 [2.9, 4.7] 
 1.0 (-1.8,8.2) 
217 
 9.2 [8.2, 10.1] 
 6.5 (1.0,9.8) 
221 
 1.5 [0.8, 2.1] 
 -0.6 (-3.8,2.5) 
291 
 0.5 [0.3, 0.6] 
 0.0 (-0.7,1.0) 
293 
 1.1 [0.7, 1.4] 
 0.8 (-3.5,6.2) 
286 
 -0.3 [-0.6, 0.1] 
 0.2 (-2.0,2.5) 
206 
 0.1 [-0.4, 0.6] 
 1.8 (-4.0,4.3) 
187 
 1.6 [1.0, 2.1] 
 -0.5 (-3.0,6.3) 
140 
 1.6 [1.2, 2.1] 
 1.4 (-3.3,4.0) 
(53,58] 
100 
 9.0 [8.0, 10.0] 
 5.3 (2.2,13.7) 
104 
 5.6 [5.0, 6.2] 
 6.2 (-1.0,11.8) 
228 
 3.2 [2.6, 3.7] 
 0.1 (-0.5,3.5) 
261 
 -0.3 [-0.5, 0.0] 
 -0.3 (-2.5,0.4) 
282 
 -1.2 [-1.5, -0.8] 
 -2.3 (-5.0,2.2) 
214 
 -2.1 [-2.6, -1.6] 
 -3.0 (-6.0,0.0) 
190 
 -1.2 [-1.8, -0.7] 
 -2.0 (-7.0,2.2) 
143 
 -2.7 [-3.5, -1.9] 
 -2.0 (-10.7,0.8) 
96 
 2.0 [1.2, 2.8] 
 2.2 (-3.1,4.0) 
(58,75]
590 
 1.3 [0.8, 1.7] 
 1.2 (-4.0,6.2) 
868 
 1.1 [0.8, 1.4] 
 1.0 (-3.6,4.5) 
1,004 
 0.9 [0.8, 1.1] 
 0.1 (-1.0,2.5) 
1,462 
 -0.1 [-0.1, 0.0] 
 0.0 (-1.5,1.3) 
1,557 
 -5.3 [-5.4, -5.1] 
 -5.0 (-9.5,-0.7) 
1,464 
 -6.7 [-6.9, -6.5] 
 -7.0 (-11.8,-1.7) 
1,147 
 -4.4 [-4.7, -4.2] 
 -4.5 (-9.5,1.0) 
930 
 -5.3 [-5.6, -5.0] 
 -4.9 (-11.0,1.0) 
687 
 -6.3 [-6.7, -6.0] 
 -6.0 (-12.4,0.0) 
(75,85] 
151 
 -0.2 [-1.3, 0.9] 
 -1.3 (-6.8,3.5) 
176 
 0.9 [0.3, 1.5] 
 1.7 (-3.5,4.9) 
185 
 1.5 [1.2, 1.9] 
 1.7 (-1.0,3.3) 
292 
 -0.3 [-0.6, -0.1] 
 0.0 (-2.2,2.3) 
299 
 -11.5 [-12.0, -11.1] 
 -10.8 (-16.8,-4.7) 
350 
 -9.0 [-9.4, -8.6] 
 -9.5 (-13.5,-2.2) 
341 
 -10.1 [-10.5, -9.7] 
 -10.5 (-15.0,-4.5) 
223 
 -10.2 [-11.0, -9.4] 
 -11.0 (-17.0,-5.5) 
196 
 -6.8 [-7.5, -6.0] 
 -5.7 (-11.5,-5.0) 
(85, Inf] 
135 
 -9.7 [-11.1, -8.2] 
 -11.7 (-22.0,2.5) 
169 
 -8.0 [-9.3, -6.6] 
 -11.7 (-18.5,1.5) 
205 
 2.7 [2.2, 3.2] 
 1.7 (-1.4,5.3) 
215 
 -3.7 [-4.3, -3.1] 
 -2.6 (-5.5,0.5) 
284 
 -22.2 [-23.0, -21.4] 
 -21.3 (-27.1,-15.2) 
269 
 -20.2 [-21.3, -19.2] 
 -19.3 (-30.0,-10.5) 
232 
 -15.7 [-16.8, -14.6] 
 -20.2 (-27.2,-8.9) 
216 
 -23.1 [-24.3, -21.9] 
 -23.2 (-31.2,-13.9) 
159 
 -16.2 [-17.5, -15.0] 
 -13.5 (-24.2,-9.0) 
All CSII recipients stratified by age
Age Group -4 -3 -2 -1 0 1 2 3 4 
(-Inf,13] 
59 
 -3.8 [-5.9, -1.7] 
 -2.2 (-7.5,6.7) 
48 
 -1.6 [-2.3, -1.0] 
 -1.2 (-5.3,2.4) 
20 
 -1.6 [-2.1, -1.0] 
 -0.6 (-3.7,0.0) 
14 
 -0.5 [-0.9, -0.1] 
 -0.7 (-1.6,1.0) 
2 
 -6.0 [-6.0, -6.0] 
 -6.0 (-6.0,-6.0) 
NA NA NA NA 
(13,19] 
78 
 -6.8 [-8.4, -5.2] 
 -7.0 (-22.0,4.5) 
85 
 7.0 [4.9, 9.0] 
 -0.5 (-4.3,12.5) 
111 
 1.0 [0.5, 1.6] 
 -0.6 (-2.8,2.8) 
101 
 -0.2 [-1.4, 1.0] 
 0.0 (-1.6,4.8) 
139 
 -7.1 [-8.4, -5.7] 
 -5.0 (-9.8,1.5) 
118 
 -8.5 [-10.2, -6.8] 
 -6.9 (-12.3,1.0) 
110 
 -7.1 [-8.6, -5.6] 
 -3.0 (-11.9,-1.8) 
57 
 1.8 [0.6, 3.0] 
 1.5 (-1.5,6.6) 
32 
 -5.2 [-6.5, -3.9] 
 -4.2 (-10.0,-0.2) 
(19,25] 
158 
 4.1 [3.0, 5.2] 
 2.5 (-5.0,12.0) 
184 
 -0.9 [-2.1, 0.4] 
 0.0 (-6.2,9.0) 
205 
 4.2 [3.5, 4.8] 
 2.0 (-1.0,7.0) 
293 
 -0.7 [-1.0, -0.5] 
 -0.2 (-2.6,2.2) 
224 
 -4.8 [-5.5, -4.1] 
 -1.8 (-12.6,3.0) 
217 
 -4.3 [-5.2, -3.5] 
 -2.2 (-7.0,1.0) 
135 
 -1.9 [-3.1, -0.8] 
 -2.3 (-11.2,8.0) 
74 
 -12.5 [-15.0, -10.0] 
 -6.0 (-32.0,1.8) 
65 
 5.6 [3.9, 7.3] 
 6.0 (-2.5,12.5) 
(25,45] 
575 
 1.0 [0.5, 1.5] 
 1.0 (-4.2,6.0) 
871 
 2.4 [2.1, 2.7] 
 2.0 (-3.6,7.0) 
1,067 
 1.2 [1.0, 1.4] 
 0.1 (-1.4,2.8) 
1,419 
 -0.3 [-0.4, -0.2] 
 -0.3 (-2.0,1.0) 
1,542 
 -7.3 [-7.5, -7.0] 
 -6.5 (-11.0,-1.7) 
1,452 
 -8.0 [-8.3, -7.7] 
 -7.2 (-12.9,-1.7) 
1,143 
 -5.7 [-6.0, -5.4] 
 -5.4 (-12.0,1.0) 
929 
 -7.2 [-7.6, -6.8] 
 -5.0 (-14.4,0.5) 
655 
 -6.3 [-6.7, -5.8] 
 -4.5 (-12.2,1.2) 
(45,65] 
230 
 1.3 [0.6, 2.1] 
 1.0 (-4.0,6.0) 
342 
 -0.4 [-0.8, 0.0] 
 -0.2 (-4.0,4.5) 
423 
 1.3 [1.1, 1.5] 
 0.2 (-0.3,2.5) 
656 
 -0.3 [-0.4, -0.2] 
 0.0 (-1.5,0.8) 
766 
 -5.6 [-5.9, -5.3] 
 -4.5 (-8.9,0.0) 
752 
 -6.6 [-6.9, -6.3] 
 -5.0 (-11.0,-1.7) 
674 
 -6.6 [-6.9, -6.2] 
 -5.5 (-11.0,0.0) 
585 
 -7.5 [-8.0, -7.1] 
 -7.5 (-13.9,-0.5) 
497 
 -7.5 [-7.9, -7.2] 
 -7.0 (-12.4,-3.5) 
(65, Inf] 
2 
 7.0 [7.0, 7.0] 
 7.0 (7.0,7.0) 
4 
 0.7 [-2.0, 3.3] 
 -2.0 (-2.0,0.7) 
17 
 2.9 [2.8, 3.1] 
 2.8 (2.8,2.8) 
38 
 0.1 [0.1, 0.1] 
 0.0 (0.0,0.2) 
42 
 -8.8 [-10.0, -7.6] 
 -3.5 (-14.2,-3.2) 
44 
 -9.0 [-9.9, -8.2] 
 -10.3 (-15.0,-0.5) 
54 
 -7.5 [-8.3, -6.6] 
 -5.1 (-12.8,-5.0) 
54 
 -7.3 [-8.2, -6.3] 
 -8.0 (-14.0,-1.0) 
29 
 -6.3 [-7.9, -4.6] 
 -2.5 (-17.0,2.5) 
All CSII recipients stratified by duration
Duration -4 -3 -2 -1 0 1 2 3 4 
(-Inf,5] 185 248 249 237 176 125 63 8 2 
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 -2.6 [-3.6, -1.5] 
 -2.2 (-10.8,5.7) 
 0.6 [-0.4, 1.6] 
 -0.8 (-7.5,4.5) 
 1.4 [0.9, 2.0] 
 -0.5 (-1.7,1.8) 
 0.9 [0.6, 1.1] 
 0.3 (-1.0,2.9) 
 -3.9 [-4.9, -2.9] 
 -3.0 (-8.5,2.9) 
 -3.0 [-4.4, -1.5] 
 -4.5 (-7.1,1.0) 
 -2.5 [-4.5, -0.5] 
 -1.9 (-7.3,3.5) 
 -8.1 [-16.8, 0.7] 
 -10.0 (-31.0,12.9) 
 -34.0 [-34.0, -34.0] 
 -34.0 (-34.0,-34.0) 
(5,10] 
184 
 -0.4 [-1.3, 0.6] 
 1.5 (-7.2,6.2) 
199 
 0.6 [0.0, 1.2] 
 1.4 (-3.8,5.0) 
220 
 2.7 [2.2, 3.1] 
 0.0 (-1.3,4.1) 
330 
 -0.2 [-0.4, 0.1] 
 -0.3 (-2.3,2.0) 
361 
 -6.1 [-6.6, -5.6] 
 -5.0 (-10.0,0.8) 
311 
 -4.0 [-4.5, -3.5] 
 -3.0 (-8.9,0.7) 
226 
 -0.9 [-1.6, -0.2] 
 -1.0 (-5.4,5.3) 
140 
 -1.0 [-2.5, 0.5] 
 2.6 (-4.8,9.0) 
106 
 4.8 [3.7, 5.9] 
 4.3 (0.0,10.5) 
(10,15] 
185 
 2.3 [1.2, 3.4] 
 1.8 (-2.8,5.3) 
243 
 5.9 [5.2, 6.6] 
 2.4 (-1.5,14.0) 
292 
 3.3 [3.0, 3.7] 
 1.7 (-0.8,7.0) 
428 
 -0.9 [-1.2, -0.7] 
 -0.5 (-1.8,0.8) 
427 
 -8.8 [-9.4, -8.3] 
 -6.0 (-14.9,-1.8) 
335 
 -7.3 [-7.8, -6.8] 
 -6.3 (-12.4,-2.0) 
365 
 -7.5 [-8.0, -7.0] 
 -7.2 (-13.5,-2.5) 
207 
 -8.8 [-9.7, -7.8] 
 -7.5 (-16.5,0.8) 
172 
 -5.5 [-6.6, -4.5] 
 -4.5 (-11.2,1.4) 
(15,20] 
140 
 2.7 [1.7, 3.8] 
 1.0 (-4.0,10.9) 
211 
 -1.2 [-2.2, -0.1] 
 -1.0 (-5.0,4.8) 
248 
 2.5 [2.0, 2.9] 
 1.2 (0.1,3.3) 
376 
 -1.4 [-1.6, -1.2] 
 -0.5 (-4.0,0.3) 
390 
 -6.7 [-7.2, -6.1] 
 -6.0 (-11.0,0.4) 
399 
 -9.2 [-9.9, -8.6] 
 -8.5 (-16.4,-1.0) 
307 
 -7.3 [-8.1, -6.6] 
 -5.0 (-14.5,1.5) 
305 
 -8.8 [-9.5, -8.1] 
 -6.5 (-14.4,0.5) 
247 
 -6.8 [-7.4, -6.1] 
 -7.8 (-12.2,-2.6) 
(20, Inf] 
408 
 1.3 [0.8, 1.8] 
 1.0 (-4.0,6.0) 
633 
 1.4 [1.1, 1.7] 
 1.8 (-3.6,5.5) 
834 
 0.4 [0.2, 0.5] 
 0.0 (-1.5,2.0) 
1,150 
 -0.1 [-0.2, 0.0] 
 0.0 (-1.6,1.0) 
1,361 
 -6.4 [-6.6, -6.2] 
 -5.5 (-10.2,-1.2) 
1,413 
 -7.9 [-8.2, -7.6] 
 -7.0 (-12.0,-1.7) 
1,155 
 -6.1 [-6.3, -5.8] 
 -5.4 (-12.0,0.0) 
1,039 
 -7.3 [-7.7, -7.0] 
 -5.5 (-13.7,-1.0) 
751 
 -7.5 [-7.9, -7.2] 
 -5.7 (-13.2,-0.5) 
HbA1c values in IFCC mmol/mol units
* IQR = interquartile range in square brackets 
** 95% CI = 95% confidence interval in round brackets 
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Supplementary Table 3 Difference in HbA1C across time with respect to CSII initiation date stratified by DAFNE
CSII, never DAFNE. Overall 
Years since CSII -4 -3 -2 -1 0 1 2 3 4 
n
median[IQR]*
mean(95%CI)**
621 
 0.7 [0.2, 1.3] 
 0.5 (-6.4,6.5) 
757 
 0.5 [0.1, 0.8] 
 -0.3 (-4.0,4.9) 
820 
 1.0 [0.8, 1.2] 
 0.4 (-1.4,2.8) 
965 
 -0.5 [-0.7, -0.3] 
 0.0 (-2.0,1.2) 
1,163 
 -7.4 [-7.8, -7.1] 
 -5.5 (-12.0,-0.8) 
1,064 
 -8.1 [-8.5, -7.7] 
 -7.0 (-13.8,-0.7) 
892 
 -5.7 [-6.1, -5.2] 
 -5.2 (-11.5,0.4) 
774 
 -7.5 [-8.1, -7.0] 
 -5.5 (-14.4,0.5) 
610 
 -6.1 [-6.7, -5.6] 
 -5.3 (-13.8,1.7) 
CSII with DAFNE Overall
Months since CSII -4 -3 -2 -1 0 1 2 3 4 
n
median[IQR]*
mean(95%CI)**
481 
 0.7 [0.2, 1.3] 
 1.2 (-5.0,6.0) 
777 
 2.5 [2.1, 3.0] 
 3.3 (-3.7,6.5) 
1,023 
 2.0 [1.8, 2.2] 
 0.0 (-1.2,2.8) 
1,556 
 -0.3 [-0.3, -0.2] 
 0.0 (-1.8,1.0) 
1,552 
 -6.0 [-6.2, -5.8] 
 -5.0 (-10.2,-0.5) 
1,519 
 -6.8 [-7.0, -6.6] 
 -5.5 (-11.6,-1.5) 
1,224 
 -6.0 [-6.2, -5.7] 
 -5.0 (-12.5,0.1) 
925 
 -7.0 [-7.4, -6.6] 
 -5.0 (-14.0,0.5) 
668 
 -6.1 [-6.4, -5.8] 
 -5.3 (-11.4,-0.5) 
HbA1c values in IFCC mmol/mol units
* IQR = interquartile range in square brackets 
** 95% CI = 95% confidence interval in round brackets 
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Supplementary Table 4  Difference in HbA1C with respect to intervention initiation date (HbA1C in percentage units) 
Difference with respect to DAFNE initiation date overall
Years since DAFNE -4 -3 -2 -1 0 1 2 3 4 
n
median[IQR]*
mean(95%CI)**
2,058 
 -0.07 [-0.14, 0.00] 
 -2.20 (-2.70,2.70) 
2,225 
 0.21 [0.15, 0.27] 
 0.00 (-2.56,2.70) 
2,775 
 0.28 [0.23, 0.32] 
 0.00 (-2.33,2.42) 
4,004 
 -0.20 [-0.23, -0.17] 
 0.00 (-2.24,2.24) 
3,163 
 -0.97 [-1.02, -0.92] 
 -2.42 (-2.93,2.33) 
2,340 
 -0.82 [-0.89, -0.76] 
 -2.38 (-3.11,2.47) 
1,754 
 -0.73 [-0.81, -0.65] 
 -2.38 (-3.06,2.61) 
1,502 
 -0.72 [-0.80, -0.63] 
 -2.42 (-3.25,2.61) 
1,233 
 -0.88 [-0.97, -0.79] 
 -2.42 (-3.39,2.61) 
Difference with respect to DAFNE initiation date by sex
Female 
1,149 
 -0.10 [-0.20, -0.01] 
 -2.20 (-2.79,2.74) 
1,251 
 0.27 [0.19, 0.36] 
 2.20 (-2.61,2.70) 
1,541 
 0.23 [0.17, 0.29] 
 0.00 (-2.33,2.38) 
2,222 
 -0.21 [-0.25, -0.17] 
 0.00 (-2.24,2.20) 
1,792 
 -1.12 [-1.18, -1.05] 
 -2.47 (-2.97,2.30) 
1,358 
 -1.09 [-1.18, -1.00] 
 -2.47 (-3.25,2.42) 
1,026 
 -0.96 [-1.07, -0.86] 
 -2.47 (-3.11,2.52) 
882 
 -0.68 [-0.79, -0.56] 
 -2.42 (-3.34,2.61) 
745 
 -0.95 [-1.07, -0.83] 
 -2.42 (-3.43,2.61) 
Male 
909 
 -0.03 [-0.13, 0.07] 
 -2.20 (-2.61,2.61) 
974 
 0.12 [0.03, 0.21] 
 0.00 (-2.52,2.70) 
1,234 
 0.34 [0.27, 0.40] 
 0.00 (-2.29,2.42) 
1,782 
 -0.19 [-0.24, -0.14] 
 0.00 (-2.29,2.24) 
1,371 
 -0.77 [-0.85, -0.69] 
 -2.42 (-2.84,2.42) 
982 
 -0.45 [-0.55, -0.36] 
 -2.24 (-2.74,2.61) 
728 
 -0.40 [-0.52, -0.29] 
 -2.29 (-3.00,2.61) 
620 
 -0.78 [-0.90, -0.65] 
 -2.42 (-3.02,2.56) 
488 
 -0.78 [-0.93, -0.63] 
 -2.38 (-3.34,2.52) 
Difference with respect to CSII initiation date overall
Years since CII -4 -3 -2 -1 0 1 2 3 4 
n
median[IQR]*
mean(95%CI)**
1,102 
 0.25 [0.16, 0.35] 
 2.24 (-2.65,2.73) 
1,534 
 0.35 [0.27, 0.42] 
 2.29 (-2.52,2.70) 
1,843 
 0.45 [0.39, 0.50] 
 2.17 (-2.27,2.41) 
2,521 
 -0.28 [-0.32, -0.23] 
 0.00 (-2.31,2.24) 
2,715 
 -1.76 [-1.81, -1.72] 
 -2.65 (-3.14,-2.20) 
2,583 
 -1.91 [-1.96, -1.87] 
 -2.76 (-3.25,-2.24) 
2,116 
 -1.55 [-1.61, -1.49] 
 -2.62 (-3.25,2.18) 
1,699 
 -1.66 [-1.72, -1.59] 
 -2.65 (-3.46,2.20) 
1,278 
 -1.56 [-1.64, -1.49] 
 -2.64 (-3.27,2.18) 
Difference with respect to CSII initiation date by sex
Female 
695 
 0.08 [-0.04, 0.20] 
 2.24 (-2.79,2.70) 
1,012 
 0.35 [0.25, 0.44] 
 2.33 (-2.52,2.65) 
1,142 
 0.37 [0.30, 0.44] 
 2.16 (-2.29,2.41) 
1,474 
 -0.10 [-0.16, -0.04] 
 0.00 (-2.30,2.28) 
1,709 
 -1.96 [-2.02, -1.91] 
 -2.74 (-3.20,-2.29) 
1,659 
 -2.03 [-2.09, -1.97] 
 -2.79 (-3.35,-2.30) 
1,379 
 -1.58 [-1.65, -1.51] 
 -2.61 (-3.34,2.18) 
1,128 
 -1.68 [-1.77, -1.60] 
 -2.67 (-3.61,2.20) 
881 
 -1.73 [-1.82, -1.64] 
 -2.70 (-3.39,-2.17) 
Male 
407 
 0.55 [0.41, 0.69] 
 2.24 (-2.47,2.79) 
522 
 0.35 [0.23, 0.47] 
 2.24 (-2.52,2.74) 
701 
 0.57 [0.48, 0.66] 
 2.22 (-2.24,2.42) 
1,047 
 -0.54 [-0.60, -0.47] 
 -2.20 (-2.33,2.20) 
1,006 
 -1.42 [-1.50, -1.34] 
 -2.52 (-3.06,2.28) 
924 
 -1.70 [-1.78, -1.62] 
 -2.61 (-3.16,-2.20) 
737 
 -1.48 [-1.58, -1.39] 
 -2.63 (-3.03,0.00) 
571 
 -1.61 [-1.71, -1.50] 
 -2.61 (-3.17,0.00) 
397 
 -1.19 [-1.32, -1.06] 
 -2.52 (-2.93,2.18) 
HbA1c values in DCCT percentage units 
* IQR = interquartile range in square brackets 
** 95% CI = 95% confidence interval in round brackets 
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Supplementary Table 5 Difference in HbA1C over time with respect to DAFNE initiation date (HbA1C percentage units) 
All DAFNE recipients
Years since DAFNE -4 -3 -2 -1 0 1 2 3 4 
n
median[IQR]*
mean(95%CI)**
2,058 
 -0.07 [-0.14, 0.00] 
 -2.20 (-2.70,2.70) 
2,225 
 0.21 [0.15, 0.27] 
 0.00 (-2.56,2.70) 
2,775 
 0.28 [0.23, 0.32] 
 0.00 (-2.33,2.42) 
4,004 
 -0.20 [-0.23, -0.17] 
 0.00 (-2.24,2.24) 
3,163 
 -0.97 [-1.02, -0.92] 
 -2.42 (-2.93,2.33) 
2,340 
 -0.82 [-0.89, -0.76] 
 -2.38 (-3.11,2.47) 
1,754 
 -0.73 [-0.81, -0.65] 
 -2.38 (-3.06,2.61) 
1,502 
 -0.72 [-0.80, -0.63] 
 -2.42 (-3.25,2.61) 
1,233 
 -0.88 [-0.97, -0.79] 
 -2.42 (-3.39,2.61) 
All DAFNE recipients stratified by HbA1C
HbA1c -4 -3 -2 -1 0 1 2 3 4 
(-Inf,53] 
154 
 1.60 [1.38, 1.83] 
 2.65 (-2.20,3.20) 
211 
 1.48 [1.30, 1.67] 
 2.52 (-2.20,2.84) 
337 
 0.52 [0.38, 0.66] 
 0.00 (-2.29,2.42) 
479 
 -0.12 [-0.21, -0.03] 
 0.00 (-2.24,2.20) 
334 
 1.34 [1.22, 1.46] 
 2.42 (0.00,2.70) 
236 
 1.12 [0.95, 1.29] 
 2.38 (-2.29,2.88) 
158 
 2.00 [1.79, 2.21] 
 2.70 (2.24,4.12) 
122 
 2.13 [1.91, 2.35] 
 3.02 (2.37,3.61) 
88 
 2.37 [2.13, 2.62] 
 3.34 (2.52,3.61) 
(53,58] 
220 
 0.89 [0.69, 1.08] 
 2.31 (-2.33,2.76) 
255 
 1.08 [0.91, 1.26] 
 2.33 (-2.29,2.86) 
285 
 0.66 [0.52, 0.79] 
 2.20 (-2.24,2.52) 
479 
 -0.46 [-0.55, -0.38] 
 0.00 (-2.24,0.00) 
311 
 0.29 [0.14, 0.43] 
 2.24 (-2.52,2.61) 
268 
 1.15 [1.00, 1.31] 
 2.33 (-2.24,2.69) 
188 
 0.37 [0.17, 0.57] 
 2.20 (-2.42,2.65) 
159 
 0.48 [0.26, 0.69] 
 2.33 (-2.52,2.61) 
116 
 0.22 [-0.03, 0.47] 
 2.33 (-2.42,2.65) 
(58,75] 
943 
 0.15 [0.06, 0.25] 
 0.00 (-2.61,2.61) 
1,048 
 0.36 [0.27, 0.44] 
 2.24 (-2.47,2.70) 
1,317 
 0.21 [0.15, 0.27] 
 0.00 (-2.29,2.38) 
1,863 
 -0.13 [-0.18, -0.09] 
 0.00 (-2.24,2.24) 
1,516 
 -0.87 [-0.94, -0.81] 
 -2.40 (-2.79,2.29) 
1,047 
 -0.64 [-0.73, -0.55] 
 -2.33 (-2.79,2.42) 
749 
 -0.19 [-0.30, -0.08] 
 -2.29 (-2.70,2.70) 
623 
 -0.19 [-0.31, -0.07] 
 -2.24 (-2.70,2.65) 
544 
 -0.20 [-0.33, -0.07] 
 -2.29 (-2.79,2.56) 
(75,85] 
411 
 -0.51 [-0.66, -0.36] 
 -2.33 (-2.70,2.61) 
392 
 -0.12 [-0.27, 0.03] 
 -2.22 (-2.70,2.74) 
474 
 0.29 [0.17, 0.40] 
 0.00 (-2.33,2.33) 
731 
 -0.25 [-0.32, -0.17] 
 0.00 (-2.29,2.20) 
551 
 -1.70 [-1.81, -1.59] 
 -2.70 (-3.32,-2.29) 
454 
 -1.72 [-1.84, -1.59] 
 -2.93 (-3.48,0.00) 
348 
 -1.93 [-2.07, -1.80] 
 -2.97 (-3.80,-2.24) 
246 
 -1.52 [-1.70, -1.34] 
 -2.88 (-3.34,2.24) 
208 
 -1.46 [-1.65, -1.26] 
 -2.79 (-3.43,2.26) 
(85, Inf] 
330 
 -1.57 [-1.77, -1.38] 
 -2.84 (-3.71,2.49) 
319 
 -1.41 [-1.57, -1.26] 
 -2.52 (-3.11,2.24) 
362 
 -0.01 [-0.15, 0.13] 
 0.00 (-2.56,2.47) 
452 
 -0.21 [-0.33, -0.10] 
 0.00 (-2.42,2.29) 
451 
 -2.96 [-3.09, -2.82] 
 -3.34 (-4.80,-2.72) 
335 
 -3.13 [-3.30, -2.97] 
 -3.71 (-4.99,-2.70) 
311 
 -2.75 [-2.93, -2.57] 
 -3.25 (-4.85,-2.36) 
352 
 -2.62 [-2.78, -2.46] 
 -3.52 (-4.53,-2.33) 
277 
 -3.28 [-3.46, -3.11] 
 -3.80 (-4.71,-2.70) 
All DAFNE recipients stratified by age
Age group -4 -3 -2 -1 0 1 2 3 4 
(13,19] 
372 
 -0.67 [-0.85, -0.50] 
 -2.49 (-3.16,2.70) 
278 
 0.14 [-0.06, 0.34] 
 1.10 (-2.88,2.72) 
202 
 0.20 [-0.01, 0.41] 
 0.00 (-2.42,2.42) 
151 
 0.43 [0.25, 0.62] 
 0.00 (-2.20,2.33) 
72 
 0.99 [0.66, 1.33] 
 2.52 (-2.49,3.24) 
9 
 1.56 [0.27, 2.86] 
 2.52 (-2.56,4.89) 
NA NA NA 
(19,25] 
244 
 0.79 [0.55, 1.03] 
 2.31 (-2.54,3.09) 
290 
 0.65 [0.46, 0.85] 
 2.47 (-2.70,2.97) 
421 
 0.33 [0.20, 0.46] 
 0.00 (-2.42,2.52) 
676 
 -0.50 [-0.58, -0.43] 
 0.00 (-2.33,0.00) 
460 
 -0.61 [-0.78, -0.45] 
 -2.38 (-2.88,2.79) 
321 
 -0.33 [-0.53, -0.12] 
 -2.24 (-3.02,2.97) 
221 
 -0.78 [-1.01, -0.55] 
 -2.33 (-3.06,2.74) 
184 
 -1.07 [-1.35, -0.78] 
 -2.42 (-4.44,2.70) 
112 
 0.22 [-0.14, 0.58] 
 2.33 (-3.84,3.34) 
(25,45] 
839 
 -0.10 [-0.20, 0.00] 
 -2.20 (-2.70,2.61) 
918 
 0.11 [0.01, 0.20] 
 0.00 (-2.52,2.65) 
1,264 
 0.16 [0.10, 0.23] 
 0.00 (-2.29,2.38) 
1,848 
 -0.14 [-0.19, -0.09] 
 0.00 (-2.24,2.24) 
1,514 
 -1.09 [-1.16, -1.02] 
 -2.52 (-3.06,2.33) 
1,165 
 -1.00 [-1.10, -0.91] 
 -2.42 (-3.25,2.42) 
847 
 -1.07 [-1.18, -0.96] 
 -2.52 (-3.25,2.61) 
718 
 -0.87 [-0.99, -0.76] 
 -2.56 (-3.25,2.56) 
564 
 -1.53 [-1.66, -1.39] 
 -2.79 (-3.52,2.42) 
(45,65] 
556 
 -0.14 [-0.27, -0.01] 
 -2.20 (-2.65,2.61) 
671 
 0.10 [-0.01, 0.20] 
 0.00 (-2.52,2.61) 
789 
 0.38 [0.30, 0.47] 
 0.00 (-2.33,2.42) 
1,146 
 -0.14 [-0.20, -0.08] 
 0.00 (-2.24,2.24) 
926 
 -1.13 [-1.21, -1.04] 
 -2.42 (-2.79,2.24) 
698 
 -0.69 [-0.80, -0.59] 
 -2.33 (-2.88,2.38) 
560 
 -0.28 [-0.40, -0.15] 
 -2.24 (-2.79,2.61) 
480 
 -0.37 [-0.50, -0.23] 
 -2.33 (-2.93,2.79) 
457 
 -0.42 [-0.56, -0.28] 
 -2.33 (-2.84,2.61) 
(65, Inf] 
47 
 1.71 [1.37, 2.05] 
 2.47 (2.24,2.70) 
68 
 1.06 [0.76, 1.37] 
 2.38 (-2.20,2.84) 
99 
 0.81 [0.62, 1.01] 
 2.20 (0.00,2.38) 
183 
 -0.63 [-0.77, -0.48] 
 0.00 (-2.33,0.00) 
191 
 -0.79 [-0.96, -0.62] 
 -2.33 (-2.65,2.24) 
147 
 -1.25 [-1.45, -1.04] 
 -2.42 (-2.74,2.24) 
126 
 -0.37 [-0.64, -0.10] 
 -2.24 (-2.66,2.33) 
120 
 -0.65 [-0.93, -0.37] 
 -2.29 (-2.88,2.61) 
100 
 -0.62 [-0.93, -0.31] 
 -2.36 (-3.25,2.45) 
All DAFNE recipients stratified by duration
Duration -4 -3 -2 -1 0 1 2 3 4 
(-Inf,5] 
468 
 -0.24 [-0.41, -0.07] 
 -2.33 (-2.93,2.74) 
512 
 0.03 [-0.12, 0.18] 
 -2.20 (-2.94,2.88) 
713 
 0.44 [0.33, 0.54] 
 0.00 (-2.33,2.42) 
927 
 -0.07 [-0.13, 0.00] 
 0.00 (-2.20,2.24) 
605 
 0.12 [-0.01, 0.25] 
 2.20 (-2.56,2.88) 
387 
 0.91 [0.73, 1.08] 
 2.47 (-2.36,3.34) 
204 
 0.79 [0.54, 1.04] 
 2.33 (-2.62,3.42) 
94 
 0.03 [-0.35, 0.41] 
 1.17 (-2.82,3.25) 
10 
 -0.80 [-2.31, 0.71] 
 -3.98 (-3.98,4.62) 
(5,10] 389 408 501 665 463 359 278 269 249 
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 0.16 [-0.02, 0.33] 
 2.24 (-2.79,2.84) 
 0.45 [0.30, 0.60] 
 2.29 (-2.52,2.74) 
 0.23 [0.13, 0.34] 
 0.00 (-2.33,2.42) 
 -0.32 [-0.40, -0.23] 
 0.00 (-2.29,2.20) 
 -0.73 [-0.86, -0.59] 
 -2.38 (-2.79,2.33) 
 -0.43 [-0.59, -0.27] 
 -2.24 (-2.81,2.56) 
 -0.64 [-0.85, -0.44] 
 -2.33 (-3.20,2.87) 
 0.28 [0.07, 0.49] 
 2.33 (-2.88,3.11) 
 -0.27 [-0.48, -0.06] 
 -2.24 (-2.97,2.74) 
(10,15] 
327 
 -0.53 [-0.70, -0.37] 
 -2.33 (-2.88,2.52) 
315 
 0.00 [-0.17, 0.17] 
 -2.24 (-2.65,2.65) 
339 
 0.07 [-0.06, 0.20] 
 0.00 (-2.33,2.47) 
536 
 -0.13 [-0.22, -0.05] 
 0.00 (-2.29,2.24) 
439 
 -1.62 [-1.75, -1.49] 
 -2.61 (-3.20,2.24) 
338 
 -1.66 [-1.82, -1.50] 
 -2.70 (-3.77,2.37) 
254 
 -1.44 [-1.62, -1.27] 
 -2.47 (-3.16,2.20) 
286 
 -1.24 [-1.42, -1.06] 
 -2.56 (-3.34,2.38) 
204 
 -1.62 [-1.83, -1.41] 
 -3.02 (-3.52,2.33) 
(15,20] 
303 
 0.12 [-0.04, 0.29] 
 0.00 (-2.52,2.61) 
332 
 0.68 [0.53, 0.83] 
 2.24 (-2.39,2.84) 
406 
 0.00 [-0.12, 0.12] 
 0.00 (-2.29,2.33) 
570 
 -0.13 [-0.22, -0.05] 
 0.00 (-2.29,2.24) 
511 
 -1.25 [-1.38, -1.13] 
 -2.52 (-2.97,2.24) 
368 
 -1.32 [-1.49, -1.16] 
 -2.61 (-3.43,2.33) 
230 
 -1.79 [-1.98, -1.60] 
 -2.72 (-3.43,2.24) 
190 
 -1.74 [-1.96, -1.53] 
 -2.74 (-4.53,2.33) 
143 
 -1.16 [-1.44, -0.88] 
 -2.65 (-3.29,2.61) 
(20, Inf] 
571 
 0.08 [-0.04, 0.19] 
 0.00 (-2.52,2.61) 
658 
 0.07 [-0.04, 0.17] 
 0.00 (-2.42,2.55) 
816 
 0.39 [0.32, 0.47] 
 0.00 (-2.29,2.42) 
1,306 
 -0.29 [-0.35, -0.24] 
 0.00 (-2.24,2.20) 
1,145 
 -1.26 [-1.34, -1.18] 
 -2.52 (-3.02,2.20) 
888 
 -1.21 [-1.30, -1.12] 
 -2.47 (-3.06,2.24) 
788 
 -0.62 [-0.72, -0.51] 
 -2.38 (-2.97,2.52) 
663 
 -0.71 [-0.83, -0.59] 
 -2.42 (-3.16,2.61) 
627 
 -0.82 [-0.95, -0.70] 
 -2.38 (-3.36,2.52) 
HbA1c values in DCCT percentage units 
* IQR = interquartile range in square brackets 
** 95% CI = 95% confidence interval in round brackets 
Supplementary Table 6 Difference in HbA1C across time with respect to CSII initiation date by strata (HbA1C in percentage units)
All CSII recipients
Years since CII -4 -3 -2 -1 0 1 2 3 4 
n
median[IQR]*
mean(95%CI)**
1,102 
 0.25 [0.16, 0.35] 
 2.24 (-2.65,2.73) 
1,534 
 0.35 [0.27, 0.42] 
 2.29 (-2.52,2.70) 
1,843 
 0.45 [0.39, 0.50] 
 2.17 (-2.27,2.41) 
2,521 
 -0.28 [-0.32, -0.23] 
 0.00 (-2.31,2.24) 
2,715 
 -1.76 [-1.81, -1.72] 
 -2.65 (-3.14,-2.20) 
2,583 
 -1.91 [-1.96, -1.87] 
 -2.76 (-3.25,-2.24) 
2,116 
 -1.55 [-1.61, -1.49] 
 -2.62 (-3.25,2.18) 
1,699 
 -1.66 [-1.72, -1.59] 
 -2.65 (-3.46,2.20) 
1,278 
 -1.56 [-1.64, -1.49] 
 -2.64 (-3.27,2.18) 
All CSII recipients stratified by HbA1c
HbA1c -48 to -36 -36 to -24 -24 to -12 -12 to 0 0 to 12 12 to 24 24 to 36 36 to 48 48 to 60
(-Inf,53] 
126 
 0.94 [0.71, 1.18] 
 2.24 (-2.31,2.90) 
217 
 2.04 [1.86, 2.21] 
 2.74 (2.24,3.05) 
221 
 -0.25 [-0.43, -0.08] 
 -2.21 (-2.50,2.38) 
291 
 0.13 [0.01, 0.25] 
 0.00 (-2.21,2.24) 
293 
 0.41 [0.26, 0.56] 
 2.22 (-2.47,2.72) 
286 
 0.18 [0.03, 0.33] 
 2.17 (-2.33,2.38) 
206 
 0.30 [0.12, 0.49] 
 2.31 (-2.52,2.55) 
187 
 -0.12 [-0.32, 0.08] 
 -2.20 (-2.42,2.73) 
140 
 0.40 [0.18, 0.61] 
 2.28 (-2.45,2.52) 
(53,58] 
100 
 2.59 [2.41, 2.77] 
 2.64 (2.35,3.40) 
104 
 1.40 [1.16, 1.64] 
 2.71 (-2.24,3.23) 
228 
 0.73 [0.57, 0.90] 
 2.16 (-2.20,2.47) 
261 
 -0.35 [-0.49, -0.22] 
 -2.18 (-2.38,2.19) 
282 
 -0.78 [-0.93, -0.63] 
 -2.36 (-2.61,2.35) 
214 
 -1.24 [-1.40, -1.08] 
 -2.42 (-2.70,0.00) 
190 
 -0.56 [-0.76, -0.37] 
 -2.33 (-2.79,2.35) 
143 
 -0.88 [-1.10, -0.65] 
 -2.33 (-3.13,2.22) 
96 
 0.77 [0.50, 1.04] 
 2.35 (-2.44,2.51) 
(58,75]
590 
 0.33 [0.21, 0.45] 
 2.26 (-2.52,2.72) 
868 
 0.25 [0.15, 0.34] 
 2.24 (-2.48,2.56) 
1,004 
 0.35 [0.28, 0.42] 
 2.16 (-2.24,2.38) 
1,462 
 -0.24 [-0.29, -0.18] 
 0.00 (-2.29,2.27) 
1,557 
 -1.71 [-1.76, -1.65] 
 -2.61 (-3.02,-2.21) 
1,464 
 -1.96 [-2.02, -1.90] 
 -2.79 (-3.23,-2.30) 
1,147 
 -1.39 [-1.46, -1.32] 
 -2.56 (-3.02,2.24) 
930 
 -1.42 [-1.51, -1.34] 
 -2.60 (-3.16,2.24) 
687 
 -1.69 [-1.78, -1.59] 
 -2.70 (-3.28,0.00) 
(75,85] 
151 
 -0.41 [-0.66, -0.17] 
 -2.27 (-2.77,2.47) 
176 
 0.10 [-0.10, 0.31] 
 2.31 (-2.47,2.60) 
185 
 0.81 [0.65, 0.98] 
 2.30 (-2.24,2.45) 
292 
 -0.21 [-0.35, -0.07] 
 0.00 (-2.36,2.36) 
299 
 -2.98 [-3.06, -2.90] 
 -3.14 (-3.68,-2.58) 
350 
 -2.64 [-2.73, -2.55] 
 -3.02 (-3.39,-2.35) 
341 
 -2.72 [-2.81, -2.63] 
 -3.11 (-3.52,-2.56) 
223 
 -2.45 [-2.61, -2.28] 
 -3.16 (-3.71,-2.65) 
196 
 -2.31 [-2.46, -2.15] 
 -2.67 (-3.20,-2.61) 
(85, Inf] 
135 
 -1.70 [-1.99, -1.40] 
 -3.22 (-4.16,2.38) 
169 
 -1.68 [-1.94, -1.43] 
 -3.22 (-3.84,2.29) 
205 
 1.02 [0.85, 1.19] 
 2.30 (-2.28,2.64) 
215 
 -1.13 [-1.30, -0.96] 
 -2.39 (-2.65,2.20) 
284 
 -4.03 [-4.13, -3.92] 
 -4.10 (-4.63,-3.54) 
269 
 -3.49 [-3.65, -3.33] 
 -3.92 (-4.89,-3.11) 
232 
 -3.05 [-3.24, -2.87] 
 -4.00 (-4.64,-2.97) 
216 
 -3.71 [-3.90, -3.51] 
 -4.28 (-5.01,-3.42) 
159 
 -3.23 [-3.42, -3.04] 
 -3.39 (-4.36,-2.97) 
All CSII recipients stratified by age
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Age Group -4 -3 -2 -1 0 1 2 3 4 
(-Inf,13] 
59 
 -0.53 [-0.96, -0.09] 
 -2.36 (-2.84,2.76) 
48 
 -0.78 [-1.13, -0.43] 
 -2.26 (-2.64,2.37) 
20 
 -1.22 [-1.65, -0.78] 
 -2.21 (-2.49,0.00) 
14 
 -0.05 [-0.68, 0.58] 
 -0.06 (-2.29,2.25) 
2 
 -2.70 [-2.70, -2.70] 
 -2.70 (-2.70,-2.70) 
NA NA NA NA 
(13,19] 
78 
 -1.23 [-1.60, -0.87] 
 -2.79 (-4.16,2.56) 
85 
 0.41 [0.02, 0.80] 
 -2.20 (-2.55,3.29) 
111 
 0.00 [-0.25, 0.24] 
 -2.21 (-2.40,2.40) 
101 
 0.11 [-0.17, 0.39] 
 0.00 (-2.29,2.58) 
139 
 -1.50 [-1.76, -1.24] 
 -2.61 (-3.04,2.29) 
118 
 -1.25 [-1.57, -0.93] 
 -2.78 (-3.28,2.24) 
110 
 -2.13 [-2.39, -1.88] 
 -2.42 (-3.24,-2.31) 
57 
 1.03 [0.68, 1.38] 
 2.29 (-2.29,2.75) 
32 
 -1.82 [-2.20, -1.43] 
 -2.54 (-3.06,-2.17) 
(19,25] 
158 
 0.94 [0.70, 1.19] 
 2.38 (-2.61,3.25) 
184 
 -0.09 [-0.34, 0.16] 
 0.00 (-2.72,2.98) 
205 
 1.13 [0.95, 1.30] 
 2.33 (-2.24,2.79) 
293 
 -0.30 [-0.44, -0.17] 
 -2.17 (-2.39,2.35) 
224 
 -0.88 [-1.08, -0.69] 
 -2.31 (-3.30,2.42) 
217 
 -1.02 [-1.22, -0.82] 
 -2.35 (-2.79,2.24) 
135 
 -0.58 [-0.85, -0.30] 
 -2.36 (-3.17,2.88) 
74 
 -1.61 [-2.05, -1.16] 
 -2.70 (-5.08,2.31) 
65 
 1.21 [0.82, 1.59] 
 2.70 (-2.38,3.29) 
(25,45] 
575 
 0.32 [0.20, 0.45] 
 2.24 (-2.53,2.70) 
871 
 0.67 [0.57, 0.77] 
 2.33 (-2.48,2.79) 
1,067 
 0.28 [0.21, 0.35] 
 2.16 (-2.28,2.41) 
1,419 
 -0.33 [-0.39, -0.27] 
 -2.18 (-2.33,2.24) 
1,542 
 -1.98 [-2.04, -1.92] 
 -2.74 (-3.16,-2.30) 
1,452 
 -2.09 [-2.15, -2.03] 
 -2.81 (-3.33,-2.30) 
1,143 
 -1.51 [-1.59, -1.43] 
 -2.65 (-3.25,2.24) 
929 
 -1.64 [-1.74, -1.55] 
 -2.61 (-3.46,2.20) 
655 
 -1.38 [-1.49, -1.27] 
 -2.56 (-3.27,2.26) 
(45,65] 
230 
 0.29 [0.10, 0.48] 
 2.24 (-2.52,2.70) 
342 
 -0.07 [-0.22, 0.07] 
 -2.17 (-2.52,2.56) 
423 
 0.66 [0.55, 0.76] 
 2.17 (-2.18,2.38) 
656 
 -0.28 [-0.37, -0.20] 
 0.00 (-2.29,2.22) 
766 
 -1.56 [-1.65, -1.47] 
 -2.56 (-2.96,0.00) 
752 
 -1.89 [-1.98, -1.81] 
 -2.61 (-3.16,-2.30) 
674 
 -1.65 [-1.75, -1.56] 
 -2.65 (-3.16,0.00) 
585 
 -1.92 [-2.02, -1.81] 
 -2.84 (-3.42,-2.20) 
497 
 -2.16 [-2.25, -2.06] 
 -2.79 (-3.28,-2.47) 
(65, Inf] 
2 
 2.79 [2.79, 2.79] 
 2.79 (2.79,2.79) 
4 
 -1.02 [-2.33, 0.30] 
 -2.33 (-2.33,-1.02) 
17 
 2.42 [2.40, 2.44] 
 2.40 (2.40,2.40) 
38 
 0.58 [0.42, 0.73] 
 0.00 (0.00,1.63) 
42 
 -2.95 [-3.06, -2.85] 
 -2.47 (-3.45,-2.45) 
44 
 -2.78 [-2.93, -2.63] 
 -3.10 (-3.52,-2.20) 
54 
 -2.36 [-2.61, -2.11] 
 -2.62 (-3.32,-2.61) 
54 
 -2.02 [-2.29, -1.75] 
 -2.88 (-3.43,-2.24) 
29 
 -1.39 [-1.87, -0.91] 
 -2.38 (-3.71,2.38) 
All CSII recipients stratified by duration
Duration -4 -3 -2 -1 0 1 2 3 4 
(-Inf,5] 
185 
 -0.83 [-1.06, -0.59] 
 -2.36 (-3.13,2.67) 
248 
 -0.03 [-0.24, 0.17] 
 -2.22 (-2.84,2.56) 
249 
 -0.34 [-0.51, -0.18] 
 -2.20 (-2.30,2.31) 
237 
 0.44 [0.29, 0.59] 
 2.18 (-2.24,2.42) 
176 
 -0.94 [-1.16, -0.72] 
 -2.42 (-2.93,2.42) 
125 
 -0.46 [-0.75, -0.17] 
 -2.56 (-2.80,2.24) 
63 
 -0.53 [-0.95, -0.12] 
 -2.32 (-2.82,2.47) 
8 
 -0.74 [-2.35, 0.87] 
 -0.91 (-4.99,3.33) 
2 
 -5.26 [-5.26, -5.26] 
 -5.26 (-5.26,-5.26) 
(5,10] 
184 
 0.25 [0.02, 0.48] 
 2.29 (-2.81,2.72) 
199 
 0.28 [0.08, 0.48] 
 2.28 (-2.49,2.61) 
220 
 0.35 [0.18, 0.52] 
 0.00 (-2.27,2.52) 
330 
 -0.43 [-0.56, -0.31] 
 -2.18 (-2.36,2.33) 
361 
 -1.47 [-1.61, -1.33] 
 -2.61 (-3.06,2.22) 
311 
 -1.11 [-1.26, -0.96] 
 -2.42 (-2.96,2.21) 
226 
 -0.29 [-0.48, -0.10] 
 -2.24 (-2.64,2.64) 
140 
 0.68 [0.39, 0.96] 
 2.39 (-2.58,2.97) 
106 
 1.49 [1.24, 1.74] 
 2.55 (0.00,3.11) 
(10,15] 
185 
 0.95 [0.73, 1.17] 
 2.31 (-2.40,2.64) 
243 
 1.22 [1.04, 1.40] 
 2.37 (-2.29,3.43) 
292 
 0.99 [0.85, 1.13] 
 2.30 (-2.22,2.79) 
428 
 -0.46 [-0.57, -0.35] 
 -2.20 (-2.31,2.22) 
427 
 -2.20 [-2.32, -2.09] 
 -2.70 (-3.51,-2.31) 
335 
 -2.07 [-2.18, -1.95] 
 -2.73 (-3.29,-2.33) 
365 
 -2.12 [-2.24, -2.00] 
 -2.81 (-3.39,-2.38) 
207 
 -1.79 [-1.99, -1.59] 
 -2.84 (-3.66,2.22) 
172 
 -1.38 [-1.60, -1.16] 
 -2.56 (-3.18,2.28) 
(15,20] 
140 
 0.57 [0.32, 0.83] 
 2.24 (-2.52,3.15) 
211 
 -0.28 [-0.50, -0.05] 
 -2.24 (-2.61,2.58) 
248 
 1.56 [1.44, 1.68] 
 2.26 (2.16,2.45) 
376 
 -0.62 [-0.73, -0.51] 
 -2.20 (-2.52,2.18) 
390 
 -1.64 [-1.77, -1.50] 
 -2.70 (-3.16,2.19) 
399 
 -2.11 [-2.24, -1.98] 
 -2.93 (-3.65,-2.24) 
307 
 -1.64 [-1.81, -1.48] 
 -2.61 (-3.48,2.29) 
305 
 -1.84 [-2.00, -1.68] 
 -2.74 (-3.46,2.20) 
247 
 -2.00 [-2.16, -1.85] 
 -2.87 (-3.27,-2.39) 
(20, Inf] 
408 
 0.32 [0.18, 0.47] 
 2.24 (-2.52,2.70) 
633 
 0.39 [0.29, 0.50] 
 2.32 (-2.48,2.65) 
834 
 0.19 [0.11, 0.27] 
 0.00 (-2.29,2.33) 
1,150 
 -0.21 [-0.27, -0.14] 
 0.00 (-2.29,2.24) 
1,361 
 -1.85 [-1.91, -1.79] 
 -2.65 (-3.08,-2.26) 
1,413 
 -2.13 [-2.19, -2.07] 
 -2.79 (-3.25,-2.30) 
1,155 
 -1.64 [-1.72, -1.57] 
 -2.65 (-3.25,0.00) 
1,039 
 -1.90 [-1.98, -1.82] 
 -2.65 (-3.40,-2.24) 
751 
 -1.88 [-1.97, -1.79] 
 -2.67 (-3.36,-2.20) 
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HbA1c values in DCCT percentage units  
* IQR = interquartile range in square brackets 
** 95% CI = 95% confidence interval in round brackets 
Supplementary Table 7 Difference in HbA1C across time with respect to CSII initiation date stratified by DAFNE (HbA1C in percentage units) 
CSII, never DAFNE. Overall 
Years since CSII -4 -3 -2 -1 0 1 2 3 4 
n
median[IQR]*
mean(95%CI)**
621 
 0.19 [0.07, 0.32] 
 2.20 (-2.74,2.74) 
757 
 -0.02 [-0.12, 0.09] 
 -2.18 (-2.52,2.60) 
820 
 0.56 [0.48, 0.64] 
 2.18 (-2.28,2.40) 
965 
 -0.30 [-0.37, -
0.22] 
 0.00 (-2.33,2.26) 
1,163 
 -1.83 [-1.91, -
1.76] 
 -2.65 (-3.25,-2.22) 
1,064 
 -1.96 [-2.04, -
1.88] 
 -2.79 (-3.41,-2.21) 
892 
 -1.53 [-1.62, -
1.43] 
 -2.62 (-3.20,2.18) 
774 
 -1.67 [-1.78, -
1.57] 
 -2.65 (-3.46,2.20) 
610 
 -1.43 [-1.55, -1.31] 
 -2.64 (-3.41,2.30) 
CSII with DAFNE Overall
Months since CSII -4 -3 -2 -1 0 1 2 3 4 
n
median[IQR]*
mean(95%CI)**
481 
 0.34 [0.20, 0.47] 
 2.26 (-2.61,2.70) 
777 
 0.70 [0.60, 0.81] 
 2.45 (-2.49,2.74) 
1,023 
 0.36 [0.28, 0.43] 
 0.00 (-2.26,2.41) 
1,556 
 -0.27 [-0.32, -
0.21] 
 0.00 (-2.31,2.24) 
1,552 
 -1.71 [-1.77, -
1.65] 
 -2.61 (-3.09,-2.20) 
1,519 
 -1.88 [-1.94, -
1.83] 
 -2.65 (-3.21,-2.29) 
1,224 
 -1.56 [-1.64, -
1.49] 
 -2.61 (-3.29,2.16) 
925 
 -1.64 [-1.73, -
1.56] 
 -2.61 (-3.43,2.20) 
668 
 -1.68 [-1.77, -1.59] 
 -2.64 (-3.20,-2.20) 
HbA1c values in DCCT percentage units 
* IQR = interquartile range in square brackets 
** 95% CI = 95% confidence interval in round brackets 
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